



Instructions for Use

# phosphoTAU ELISA



**Order Number:**

847-0108000104

96 reactions



This documentation describes the state at the time of publishing. It needs not necessarily agree with future versions.  
Subject to change!

Print-out and further use permitted with indication of source.

© Copyright 2020, Roboscreen GmbH

**Manufacturer:**

Roboscreen GmbH  
Hohmannstraße 7  
04129 Leipzig  
Germany

Phone: +49 341 989734 0  
Fax: +49 341 989734 199

[www.roboscreen.com](http://www.roboscreen.com)  
[info@roboscreen.com](mailto:info@roboscreen.com)

---

**Publication No.:** Manual\_phosphoTAU ELISA\_e\_rev10

10/2020

## Contents

1	Introduction .....	2
1.1	Intended use.....	2
1.2	Warranty and technical support .....	2
1.3	Notes on the use of this instruction for use .....	3
2	Safety precautions.....	4
3	Test principle.....	6
4	Performance assessment .....	7
5	Kit components .....	9
6	Preparation of components.....	11
6.1	1X Wash solution.....	11
6.2	Standards D3.1-D3.6.....	11
6.3	Controls D7 and D8.....	11
6.4	1X HRP conjugate .....	12
7	Storage and expiry date.....	13
8	Components not included in the kit .....	13
9	Procedure notes .....	14
10	Specimen collection and storage.....	15
10.1	Specimen collection.....	15
10.2	Specimen storage .....	15
10.3	Specimen dilution .....	16
11	Test procedure .....	17
12	Data analysis .....	19
12.1	Quality criteria of the assay .....	19
12.2	Calculation of unknown phosphorylated tau concentration .....	19
13	Expected values.....	20
14	References .....	21

# 1 Introduction

## 1.1 Intended use

The phosphoTAU ELISA is an enzyme immunoassay intended for the quantitative determination of phosphorylated tau in human cerebrospinal fluid (CSF) for supporting diagnosis of Alzheimer's disease (AD). The development of Alzheimer's disease is characterized by three stages, as defined by the US National Institute on Aging workgroups:

- a preclinical stage of Alzheimer's Disease,
- the mild cognitive impairment (MCI) stage due to AD and
- dementia stage due to AD.

Phosphorylated tau in CSF shows at least comparable diagnostic specificity and sensitivity to other diagnostic available tests for Alzheimer's disease.

## 1.2 Warranty and technical support

The manufacturer guarantees the correct functioning of the kit for the applications described in the instruction for use (IFU). During the warranty period, phosphoTAU ELISA allows for precise and reproducible data collection in connection with superior sensitivity. Any warranty claims shall only be valid if the general principles of Good Laboratory Practice (GLP) and the manufacturer's recommendations are observed.

To improve the application and design, Roboscreen GmbH reserves the right of product replacement or modification. The manufacturer may be contacted at any time for questions and problems or technical support concerning the quantification of phosphorylated tau in CSF.



---








### CONSULT INSTRUCTIONS FOR USE

This package insert must be read carefully prior to use. Package insert instructions must be followed accordingly. Reliability of results cannot be guaranteed if there are any deviations from the instructions in this package insert.

---

### 1.3 Notes on the use of this instruction for use

For easy reference and orientation, the IFU uses the following warning and information symbols as well as the shown methodology:

	REF Catalogue number
	Content Contains sufficient reagents for <N> tests
	Storage conditions
	Consult instructions for use
	Expiration date
	Manufactured by
	For single use only

The following abbreviations are used in the IFU:

AD	Alzheimer's disease
CSF	Cerebrospinal fluid
CV	Coefficient of variation
ELISA	Enzyme-linked immunosorbent assay
GLP	Good Laboratory Practice
HRP	Horseradish peroxidase
OD	Optical density
RT	Room temperature (18-25°C)
TMB	Tetramethylbenzidine

## 2 Safety precautions

---

We recommend reading this chapter thoroughly before using this kit, to ensure the safety of the user and error-free utilization.

Any safety instructions and additional information of this IFU must be observed at all times.

---

Read and make sure you understand the operating instructions completely and thoroughly before carrying out the test. Use the currently valid version from the kit.

Notify the respective supplier in writing within one week from receiving the merchandise, should the test pack be substantially damaged. Damaged components must not be used to carry out the assay, however, they should be kept until the transport damages are finally settled.

Comply with Good Laboratory Practice and safety regulations. Wear laboratory coats, disposable Latex gloves and safety goggles whenever the need arises.

Reagents of this kit which contain hazardous substances may cause irritations to eyes and skin. See indications under COMPONENTS OF THE KIT and on the labels. Safety data sheets of this product are available upon request.

Chemicals and prepared or used reagents shall be disposed of as hazardous waste in compliance with the respective national regulations.

The cleaning staff has to be instructed by experts with regard to any potential risks and the appropriate handling of such substances.

Avoid any contact with stopping solution. This may cause irritations to the skin and chemical burns.



---

**FOR SINGLE USE ONLY!**

This kit is made for single use only!

**ATTENTION!**


Don't eat or drink components of the kit!

The kit shall only be handled by educated personnel in a laboratory environment!

---

### 3 Test principle

This kit works by means of a monoclonal antibody that specifically recognizes amino acids 117-124 of the human tau protein, which is immobilized on the surface area of the microtiter plate. Phosphorylated tau protein from samples, standards and controls is trapped by this antibody in presence of another peroxidase conjugated monoclonal detection antibody that specifically recognizes phosphorylated tau in the area of amino acids 1-200. Amount of bound conjugated antibody is estimated using chromogenic substrate tetra-methylbenzidine (TMB). The concentration of phosphorylated tau protein is proportional to the obtained optical density.



1. Ready-to-use: Capture antibody coated on well plate
2. Binding of target antigen by capture antibody and incubation of HRP-conjugated antibody
3. Direct detection using a HRP-conjugated antibody



## 4 Performance assessment

The table below shows typical data for calibration curves. Do not use for calculation!


Standard	Phosphorylated Tau (pg/ml)	3 h Incubation 150 rpm* (21,5 ± 3,5 °C)	
		OD <sub>mean</sub>	OD/OD <sub>max</sub> (%)
D3.1	930	2.693	100
D3.2	250	1.687	62
D3.3	110	1.194	44
D3.4	60	0.402	15
D3.5	32	0.242	9
D3.6	15	0.099	4

\* Shakers have different forces due to their specifications (deflection in mm) at a frequency of 150 rpm (see note page 17).


The table summarizes sensitivity and specificity related to determined cutoff.

Analytical Sensitivity (Limit of Detection)	15 pg/mL	Measurable as OD > mean OD of the 10-fold measurement of a negative sample + 3 times standard deviation.
Cut-off	51 pg/mL	Each laboratory must establish its own cut-off values.
Clinical sensitivity	86.5 %	AD/MCI patients (n=64)
Clinical specificity	92.2 %	Controls (n=37)









The analysis of CSF levels of phosphorylated tau using the phosphoTAU ELISA in patients with Alzheimer's disease (n = 37) and control patients (n = 64) showed a significant difference between the patient groups (p <0.001) with a sensitivity of 86.5% and specificity of 92.2%. The associated ROC analysis showed 97.1% with p <0.001 and a Youden-Index of 0.79.






A comparative analysis (deming regression) of the phosphoTAU ELISA measurements to an available commercial reference method shows a good correlation with a correlation coefficient (Pearson) of 0.88 with p <0.0001.



## 5 Kit components

Component	 96	Description
Immunostrips <b>D1</b>	12 x 8	Coated immunostrips containing anti- tau antibody, blocked and stabilized. Ready to use.
40X Wash buffer <b>D2</b>	1 x 50 ml	40X Wash buffer containing PBS, protein detergent and proclin 300.
Standards	6 x 3	Dried phosphorylated tau standards for preparing a standard curve for quantification of phosphorylated tau in unknown cerebrospinal fluid samples. Containing PBS, protein and proclin 300.
<b>D3.1</b>	 3	930 pg phosphorylated tau
<b>D3.2</b>	 3	250 pg phosphorylated tau
<b>D3.3</b>	 3	110 pg phosphorylated tau
<b>D3.4</b>	 3	60 pg phosphorylated tau
<b>D3.5</b>	 3	32 pg phosphorylated tau
<b>D3.6</b>	 3	15 pg phosphorylated tau
20X HRP conjugate <b>D5</b>	 1 ml	Monoclonal anti-phospho-Tau antibody conjugated with horseradish peroxidase, 20X concentrate containing TRIS buffer, albumin, detergent and stabilizers (Kathon, Bronidox).
Assay buffer <b>D6</b>	50 ml	Assay buffer containing PBS, protein, detergent and proclin 300. Ready to use.

## Kit components

Component	 96	Description
Control high <b>D7</b>	 3	Dried phosphorylated tau high positive control. Containing PBS, protein and proclin 300.
Control low <b>D8</b>	 3	Dried phosphorylated tau low positive control. Containing PBS, protein and proclin 300.
Staining solution <b>D9</b>	20 ml	TMB/peroxide solution. Ready to use.
Stop solution <b>D10</b>	25 ml	1 M sulphuric acid. Ready to use.
Sealing tape	1	
Instruction for use	1	

## 6 Preparation of components

### 6.1 1X Wash solution

Dilute 40X wash buffer D2 using de-ionized or bi-distilled water before the first wash step of the immunoassay.

Volume of 1X Wash solution	Volume of 40X Wash buffer D2	Volume of de-ionized or bi-distilled water
400 ml	10 ml	390 ml
600 ml	15 ml	585 ml
800 ml	20 ml	780 ml
1000 ml	25 ml	975 ml

### 6.2 Standards D3.1-D3.6

Add 0.5 ml of assay buffer D6 to each standard vial D3.1 – D3.6 and mix quickly, e.g. within 2 s by vortex.

### 6.3 Controls D7 and D8

Add 0.5 ml of assay buffer D6 to each control vial D7 and D8 and mix quickly, e.g. within 2 s by vortex.

### 6.4 1X HRP conjugate

Dilute 20X HRP conjugate D5 at ratio 1:15\* with assay buffer D6. Mix by means of shaking the tube.

Number of immuno strips	Volume of 20X HRP D5	Volume of assay buffer D6
1 - 4	0.2 ml	2.8 ml
5 - 8	0.4 ml	5.6 ml
9 - 12	0.6 ml	8.4 ml

\* Dilution of the conjugate is 1:15. In the test, the conjugate is present at a dilution of 1:20 by the addition of 25 µl standard / control / sample to 75 µl 1:15 diluted HRP conjugate.

## 7 Storage and expiry date

The kit is delivered at ambient temperature and should be stored at  $6 \pm 4$  °C. Protect from heat and direct sunlight. Under these conditions, the kit has a life time as indicated on the kit box while retaining its endurance and stability.

Prepared kit components have the following expiry dates:

Component	Preparation step	Expiry date
D1	Coated immunostrips after opening of bag, taking out of strips and closing of bag.	At $6 \pm 4$ °C up to 4 weeks.
D2	1X Ready-to-use wash solution.	At $6 \pm 4$ °C up to 4 weeks.
D3.1-D3.6	Standards D3.1-D3.6 dissolved in D6.	At $6 \pm 4$ °C up to 4 h.
D7, D8	Controls D7 and D8 dissolved in D6.	At $6 \pm 4$ °C up to 4 h.
D5	Ready-to-use 1X HRP-conjugate 1:15 diluted.	At $6 \pm 4$ °C up to 4 h.

## 8 Components not included in the kit

- Calibrated micropipettes with CV < 3 %  
Volume: 10-100 µL; 100-1000 µL
- 8-channel micropipette with reagent reservoirs
- Plate shaker\* 100-1000 rpm; e.g. Rotamax 120.
- Vortex mixer
- Automated or semi-automated ELISA plate washing system
- Bi-distilled or de-ionized water
- Paper towels, pipette tips and timer
- ELISA plate reader for reading absorbance at 450 and 620 nm
- Polypropylene tubes for sample dilution

\* Shakers have different forces due to their specifications (deflection in mm) at a frequency of 150 rpm (see note page 17).

## 9 Procedure notes

Any improper handling of samples or modification of the test procedure may influence the results. The indicated volumes, incubation times, temperatures and pretreatment steps must be followed strictly regarding this instruction.

Be sure that required reagents, materials and devices are prepared ready at the appropriate time. Allow staining solution D9 to reach room temperature ( $21.5 \pm 3.5$  °C). Mix assay buffer D6 and 20X HRP conjugate D5 by vortex before use.

Avoid contamination of reagents, pipettes and immunostrips/tubes by use of different disposables between different samples and components. Do not interchange caps. Do not re-use any well, tube or reagent.

All measurements can be done in **single determinations**; however a dual determination increases the safety of the results and allows additional evaluations for the precision of the measurements.

For duplicate determinations,  $R^2$  of the standard curve should be  $\geq 0.99$ .

It is recommended to use a pipetting scheme to apply all STD, CTRL and samples.

Solution of 1X HRP conjugate D5, staining solution D9 and stop solution D10 should be transferred by 8-channel micropipette or a multistep pipette (with reservoir) to all wells of the immunostrips.

Washing should be done by 8-channel micropipette or ELISA plate washer.

Avoid drying and over stressing of wells and control exact washing of all wells.



## 10 Specimen collection and storage

The Alzheimer's Biomarker Standardization Initiative provides the following recommendations for the pre-analytical and analytical aspects for AD biomarker testing in CSF (Vanderstichele et al., 2012).

### 10.1 Specimen collection

Lumbar puncture may be performed at the vertebral body L3-L5 with the patient either sitting or lying down. Use a small diameter (0.7 mm and 22 G), preferably not traumatic needle. A small-gauge needle will make a smaller hole in the Dura mater, aiding healing, and not traumatic needle will reduce the chance of blood contamination in the CSF.

Each laboratory should use one kind of polypropylene tubes only. Glass or polystyrene tubes should in no circumstances be used. Tubes of the smallest volume should be used, and these should be filled to at least 50 % of their volume. It is important to have carefully recorded and validated details concerning each stored sample so that any investigator when using these samples has a precise history of the sample.

Centrifugation is only required for visually hemorrhagic samples. Centrifuge immediately with recommended 2000 x g at RT for 10 min.

### 10.2 Specimen storage

It is recommended to freeze samples and store at -80 °C for long time storage. It is recommended to limit the number of freeze /thaw cycles to a maximum of 1-2. Samples should be stored no longer than 2 years.

---

#### Note

For dilution of CSF use polypropylene tubes or dilute directly onto immunostrips D1.

---

### **10.3 Specimen dilution**

Samples showing an OD higher than OD of highest standard D3.1 should be diluted before test procedure using assay buffer D6.

## 11 Test procedure

1. Transfer 75  $\mu\text{L}$  of 1X HRP conjugate in each well.
2. Afterwards pipet 25  $\mu\text{L}$  of each standard, controls and patient samples into the respective wells of plate.
3. The sequence of pipetting steps can be reversed.
4. Mix thoroughly e.g. by pipette at least 5 times.
5. Cover plate with lid or foil.
6. Incubate immune plate for  $3 \text{ h} \pm 10 \text{ min}$  at  $21.5 \pm 3.5 \text{ }^\circ\text{C}$  and  $150 \pm 15 \text{ rpm}$ .

### NOTE

Shakers have different forces due to their deflection at a frequency of 150 rpm. The calculation of the acceleration (a) according to the formula  $a = 4 \pi^2 r n^2$  should give a value of  $2.5 \text{ m/s}^2$ .

Radius (mm)	Number of revolutions (rpm)
10	150
5	212
3	274
1,5	387
0.5	671

$$\pi^2 = 9.87, r \text{ in m (10 mm = 0,01 m) and } n \text{ in r/s (150 rpm/60 = 2,5 r/s)}$$

7. Wash plate 5 x with 300  $\mu\text{L}$ /well of 1X wash solution using an automatic ELISA plate washer.

---

### Note

Alternatively, when performed manually, discard incubation solution. Remove excess solution after washing by tapping immunostrip on paper towel.

---

8. Pipette 100  $\mu$ L of staining solution D9 into each well.
9. Incubate plate at RT in the dark for 30 min.
10. Stop the substrate reaction by adding 150  $\mu$ L of stop solution D10 into each well. Briefly mix contents in the plate reader.
11. Measure optical density with a photometer at 450 nm using 620 nm as reference wave length within 15 min after stopping.

---

### Note

In samples with a high concentration of phosphorylated tau formed dye may be precipitated due to intensive staining. Therefore, 15 min time lapse until the measurement takes place are recommended.

---

## 12 Data analysis

### 12.1 Quality criteria of the assay

- Concentration of positive control **D7** and **D8** should be according to the certificate of analysis

### 12.2 Calculation of unknown phosphorylated tau concentration

For the determination of the concentration of phosphorylated tau in controls and samples the automatic data analysis by means of reader software, usually the logistic regression with 4 or 5 parameters or logit-log method is recommended. The standard curve typically shows a linear progression between the plateau of the highest standard D3.1 (930 pg/ml) and the lowest standard D3.6 (15 pg/ml).

---

#### Note

Samples with a measured OD smaller than the OD of the lowest standard D3.6 can be reported in terms of the concentration of phosphorylated TAU protein <15 pg/ml.

---

## 13 Expected values

### Note

Expected values are calculated from data of first clinical validation stage.  
All data should to be handled as preliminary.

Variable	phosphoTAU
Classification variable	AD_CO
Sample size	101
AD group	37 (36.63%)
Control group	64 (63.37%)
Area under the ROC curve (AUC)	0.971
Standard Error <sup>a</sup>	0.0131
95% Confidence interval <sup>b</sup>	0.916 to 0.994
z statistic	35.824
Significance level P (Area=0.5)	<0.0001
Youden index J	0.7867
95% Confidence interval <sup>a</sup>	0.6757 to 0.8378
Associated criterion	>51
95% Confidence interval <sup>a</sup>	>42 to >58
Sensitivity	86.49
Specificity	92.19

## 14 References

**Vanderstichele H, et al. 2012.** Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. *Alzheimers Dement.* Jan; 8(1):65-73. doi: 10.1016/j.jalz.2011.07.004. Epub 2011 Nov 2., 2012.

